Altogether, our study sheds light not only on anti-PD-1/PD-L1 resistance in cSCC, HNSCC, and melanoma patients but also on potential biomarkers to predict the response to this therapy and possible alternative treatments for these diseases. Here, CD274 is linked to melanoma.